Hasil Pencarian - Veronica Mattiello

  • Menampilkan 1 - 7 hasil dari 7
Perbaiki Hasil
  1. 1
    Should treatment of hypogammaglobulinemia with immunoglobulin replacement therapy (IgRT) become standard of care in patients with chronic lymphocytic leukemia?

    Should treatment of hypogammaglobulinemia with immunoglobulin replacement therapy (IgRT) become standard of care in patients with chronic lymphocytic leukemia? oleh Alessandro Noto, Ramona Cassin, Veronica Mattiello, Marta Bortolotti, Marta Bortolotti, Gianluigi Reda, Wilma Barcellini

    Diterbitkan 2023-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study

    Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study oleh Gianluigi Reda, Bruno Fattizzo, Ramona Cassin, Veronica Mattiello, Tatiana Tonella, Diana Giannarelli, Ferdinando Massari, Agostino Cortelezzi

    Diterbitkan 2018-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Epidemiology and treatment approaches in management of invasive fungal infections in hematological malignancies: Results from a single-centre study.

    Epidemiology and treatment approaches in management of invasive fungal infections in hematological malignancies: Results from a single-centre study. oleh Nicola Stefano Fracchiolla, Nicola Stefano Fracchiolla, Mariarita Sciumè, Nicola Orofino, Francesca Guidotti, Anna Grancini, Fabrizio Cavalca, Alessandra Freyrie, Maria Cecilia Goldaniga, Dario Consonni, Veronica Mattiello, Loredana Pettine, Agostino Cortelezzi

    Diterbitkan 2019-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi

    Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi oleh Giulia Zamprogna, Anna Maria Frustaci, Giovanna Travi, Chiara Borella, Gianluigi Reda, Marina Motta, Marina Deodato, Elisa Bossi, Veronica Mattiello, Maria Beatrice Ferrari, Giulia Cotilli, Carlo Gambacorti-Passerini, Roberto Cairoli, Massimo Puoti, Alessandra Tedeschi

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    PB1942: PARTIAL RESPONSE WITH LYMPHOCYTOSIS (PR-L) IS NOT APPLICABLE FOR ACALABRUTINIB. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE.

    PB1942: PARTIAL RESPONSE WITH LYMPHOCYTOSIS (PR-L) IS NOT APPLICABLE FOR ACALABRUTINIB. AN ITALIAN MULTICENTER EXPERIENCE OF REAL LIFE. oleh Idanna Innocenti, Antonio Mosca, Annamaria Tomasso, Andrea Galitzia, Lydia Scarfò, Eugenio Galli, Roberta Laureana, Giulia Benintende, Veronica Mattiello, Francesca Morelli, Sabrina Chiriu, Maria Ilaria Del Principe, Giulia Zamprogna, Massimo Gentile, Nicole Fabbri, Francesco Autore, Paolo Sportoletti, Alberto Fresa, Gioacchino Catania, Marta Coscia, Alessandra Tedeschi, Alessandro Sanna, Marzia Varettoni, Paolo Ghia, Roberta Murru, Luca Laurenti

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study

    Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study oleh Andrea Visentin, Andrea Visentin, Francesca Romana Mauro, Gioachino Catania, Alberto Fresa, Candida Vitale, Alessandro Sanna, Veronica Mattiello, Francesca Cibien, Paolo Sportoletti, Massimo Gentile, Gian Matteo Rigolin, Francesca Maria Quaglia, Roberta Murru, Alessandro Gozzetti, Stefano Molica, Monia Marchetti, Stefano Pravato, Francesco Angotzi, Alessandro Cellini, Lydia Scarfò, Gianluigi Reda, Marta Coscia, Luca Laurenti, Paolo Ghia, Robin Foà, Antonio Cuneo, Livio Trentin, Livio Trentin

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an adverse biological profile: results of the GIMEMA phase II LLC1518 – VERITAS study

    High rate of durable responses with undetectable minimal residual disease with front-line venetoclax and rituximab in young, fit patients with chronic lymphocytic leukemia and an a... oleh Francesca R. Mauro, Irene Della Starza, Monica Messina, Gianluigi Reda, Livio Trentin, Marta Coscia, Paolo Sportoletti, Lorella Orsucci, Valentina Arena, Gloria Margiotta Casaluci, Roberto Marasca, Roberta Murru, Luca Laurenti, Fiorella Ilariucci, Caterina Stelitano, Donato Mannina, Massimo Massaia, Gian Matteo Rigolin, Lydia Scarfò, Monia Marchetti, Luciano Levato, Monica Tani, Annalisa Arcari, Gerardo Musuraca, Marina Deodato, Piero Galieni, Valeria Belsito Patrizi, Daniela Gottardi, Anna Marina Liberati, Annamaria Giordano, Maria Chiara Molinari, Daniela Pietrasanta, Veronica Mattiello, Andrea Visentin, Candida Vitale, Francesco Albano, Antonino Neri, Lucia Anna De Novi, Maria Stefania De Propris, Mauro Nanni, Ilaria Del Giudice, Anna Guarini, Paola Fazi, Marco Vignetti, Alfonso Piciocchi, Antonio Cuneo, Robin Foà

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: